Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy

Human Gene Therapy

Volumn 24, Issue 5, 2013, Pages 479-488

  Koo, Taeyoung ^a   Wood, Matthew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AVI 5038; DRISAPERSEN; DYSTROPHIN; ETEPLIRSEN; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PLACEBO; PRO 044; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; GENE DELETION; GENE EXPRESSION; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PATIENT MOBILITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STEM CELL TRANSPLANTATION; WALKING;

CLINICAL TRIALS AS TOPIC; DYSTROPHIN; EXONS; GENETIC THERAPY; HUMANS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES, ANTISENSE; RNA PRECURSORS;

EID: 84877872340     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.234     Document Type: Review

References (84)

1. Aartsma-Rus, A., Bremmer-Bout, M., Janson, A.A., et al. (2002). Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul. Disord. 12(Suppl 1), S71-7.
2. Aartsma-Rus, A., Janson, A.A., Kaman, W.E., et al. (2003). Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum. Mol. Genet. 12, 907-914.
3. Aartsma-Rus, A., Janson, A.A., Kaman, W.E., et al. (2004). Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am. J. Hum. Genet. 74, 83-92.
4. Aartsma-Rus, A., De Winter, C.L., Janson, A.A., et al. (2005). Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides. 15, 284-297.
5. Aartsma-Rus, A., van Deutekom, J.C., Fokkema, I.F., et al. (2006). Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34, 135-144.
6. Aartsma-Rus, A., Fokkema, I., Verschuuren, J., et al. (2009). Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum. Mutat. 30, 293-299.
7. Aartsma-Rus, A., Houlleberghs, H., van Deutekom, J.C., et al. (2010). Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing. Oligonucleotides 20, 69-77.
8. Abes, S., Moulton, H.M., Clair, P., et al. (2006). Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J. Control. Release 116, 304-313.
9. Alter, J., Lou, F., Rabinowitz, A., et al. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 12, 175-177.
10. Amantana, A., Moulton, H.M., Cate, M.L., et al. (2007). Phar-macokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug. Chem. 18, 1325-1331.
11. Aoki, Y., Yokota, T., Nagata, T., et al. (2012). Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc. Natl. Acad. Sci. U.S.A. 109, 13763-13768.
12. Arechavala-Gomeza, V., Graham, I.R., Popplewell, L.J., et al. (2007). Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum. Gene Ther. 18, 798-810.
13. Askari, F.K., and McDonnell, W.M. (1996). Antisense-oligonucleotide therapy. N. Engl. J. Med. 334, 316-318.
14. Benchaouir, R., Meregalli, M., Farini, A., et al. (2007). Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell. Stem Cell 1, 646-657.
15. Bennett, C.F., and Swayze, E.E. (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259-293.
16. Beroud, C., Tuffery-Giraud, S., Matsuo, M., et al. (2007). Multi-exon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum. Mutat. 28, 196-202.
17. Betts, C., Saleh, A.F., Arzumanov, A.A., et al. (2012). Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol. Ther. Nuclei Acids 1, e38.
18. Bresolin, N., Castelli, E., Comi, G.P., et al. (1994). Cognitive impairment in Duchenne muscular dystrophy. Neuromuscul. Disord. 4, 359-369.
19. Brutsaert, D.L. (2003). Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol. Rev. 83, 59-115.
20. Bushby, K., Muntoni, F., and Bourke, J.P. (2003). 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul. Disord. 13, 166-172.
21. Cibis, G.W., Fitzgerald, K.M., Harris, D.J., et al. (1993). The effects of dystrophin gene mutations on the ERG in mice and humans. Invest. Ophthalmol. Vis. Sci. 34, 3646-3652.
22. Cirak, S., Arechavala-Gomeza, V., Guglieri, M., et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphoro-diamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378, 595-605.
23. Cirak, S., Feng, L., Anthony, K., et al. (2012). Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol. Ther. 20, 462-467.
24. Costa, M.F., Oliveira, A.G., Feitosa-Santana, C., et al. (2007). Red-green color vision impairment in Duchenne muscular dystrophy. Am. J. Hum. Genet. 80, 1064-1075.
25. Crisp, A., Yin, H., Goyenvalle, A., et al. (2011). Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum. Mol. Genet. 20, 413-421.
26. Dias, N., and Stein, C.A. (2002). Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther. 1, 347-355.
27. Eckstein, F. (2000). Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev. 10, 117-121.
28. Emery, A.E.H. (1993). Duchenne muscular dystrophy. (Oxford University Press, Oxford) pp. 392.
29. Errington, S.J., Mann, C.J., Fletcher, S., and Wilton, S.D. (2003). Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene. J. Gene Med. 5, 518-527.
30. Farini, A., Razini, P., Erratico, S., et al. (2009). Cell based therapy for Duchenne muscular dystrophy. J. Cell. Physiol. 221, 526-534.
31. Fletcher, S., Honeyman, K., Fall, A.M., et al. (2006). Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J. Gene Med. 8, 207-216.
32. Fletcher, S., Honeyman, K., Fall, A.M., et al. (2007). Morpholino oligomer-mediated exon skipping averts the onset of dys-trophic pathology in the mdx mouse. Mol. Ther. 15, 1587-1592.
33. Fuentes-Mera, L., Rodriguez-Munoz, R., Gonzalez-Ramirez, R., et al. (2006). Characterization of a novel Dp71 dystrophin-associated protein complex (DAPC) present in the nucleus of HeLa cells: members of the nuclear DAPC associate with the nuclear matrix. Exp. Cell Res. 312, 3023-3035.
34. Gebski, B.L., Mann, C.J., Fletcher, S., and Wilton, S.D. (2003). Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum. Mol. Genet. 12, 1801-1811.
35. Goemans, N.M., Tulinius, M., van den Akker, J.T., et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 364, 1513-1522.
36. Goemans, N., Klingels, K., van den Hauwe, M., et al. (2013). Test-retest reliability and developmental evolution of the 6-min walk test in Caucasian boys aged 5-12 years. Neuromuscul. Disord. 23, 19-24.
37. Goyenvalle, A., Wright, J., Babbs, A., et al. (2012). Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy. Mol. Ther. 20, 1212-1221.
38. Graham, I.R., Hill, V.J., Manoharan, M., et al. (2004). Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleo-tide arrays. J. Gene Med. 6, 1149-1158.
39. Heemskerk, H.A., De Winter, C.L., De Kimpe, S.J., et al. (2009). In vivo comparison of 2¢-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J. Gene Med. 11, 257-266.
40. Heemskerk, H., De Winter, C., van Kuik, P., et al. (2010). Pre-clinical PK and PD studies on 2¢-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol. Ther. 18, 1210-1217.
41. Hudziak, R.M., Barofsky, E., Barofsky, D.F., et al. (1996). Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 6, 267-272.
42. Ivanova, G.D., Arzumanov, A., Abes, R., et al. (2008). Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res. 36, 6418-6428.
43. Iversen, P.L. (2001). Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr. Opin. Mol. Ther. 3, 235-238.
44. Iversen, P.L., Aird, K.M., Wu, R., et al. (2009). Cellular uptake of neutral phosphorodiamidate morpholino oligomers. Curr. Pharm. Biotechnol. 10, 579-588.
45. Jearawiriyapaisarn, N., Moulton, H.M., Buckley, B., et al. (2008). Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol. Ther. 16, 1624-1629.
46. Kinali, M., Arechavala-Gomeza, V., Feng, L., et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8, 918-928.
47. Koenig, M., Hoffman, E.P., Bertelson, C.J., et al.(1987). Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50, 509-517.
48. Koo, T., Malerba, A., Athanasopoulos, T., et al. (2011). Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of alpha1-syntrophin and alpha-dystrobrevin in skeletal muscles of mdx mice. Hum. Gene Ther. 22, 1379-1388.
49. Kurreck, J. (2003). Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270, 1628-1644.
50. Lu, Q.L., Morris, G.E., Wilton, S.D., et al. (2000). Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J. Cell Biol. 148, 985-996.
51. Lu, Q.L., Mann, C.J., Lou, F., et al. (2003). Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med. 9, 1009-1014.
52. Lu, Q.L., Rabinowitz, A., Chen, Y.C., et al. (2005). Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl. Acad. Sci. U.S.A. 102, 198-203.
53. Malerba, A., Boldrin, L., and Dickson, G. (2011). Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity. Nucleic Acid Ther. 21, 293-298.
54. Manzur, A.Y., Kinali, M., and Muntoni, F. (2008). Update on the management of Duchenne muscular dystrophy. Arch. Dis. Child 93, 986-990.
55. Moulton, H.M., Fletcher, S., Neuman, B.W., et al. (2007). Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem. Soc. Trans. 35, 826-828.
56. Muntoni, F., Torelli, S., and Ferlini, A. (2003). Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2, 731-740.
57. Opalinska, J.B., and Gewirtz, A.M. (2002). Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1, 503-514.
58. Peault, B., Rudnicki, M., Torrente, Y., et al. (2007). Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol. Ther. 15, 867-877.
59. Popplewell, L.J., Adkin, C., Arechavala-Gomeza, V., et al. (2010). Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: implications for future clinical trials. Neuromuscul. Disord. 20, 102-110.
60. Popplewell, L.J., Graham, I.R., Malerba, A., and Dickson, G. (2011). Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle. Methods Mol. Biol. 709, 153-178.
61. Pramono, Z.A., Takeshima, Y., Alimsardjono, H., et al. (1996). Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxy-nucleotide complementary to an exon recognition sequence. Biochem. Biophys. Res. Commun. 226, 445-449.
62. Quenneville, S.P., Chapdelaine, P., Skuk, D., et al. (2007). Auto-logous transplantation of muscle precursor cells modified with a lentivirus for muscular dystrophy: human cells and primate models. Mol. Ther. 15, 431-438.
63. Sazani, P., Blouch, R., Weller, D., et al. (2009). Avi 5038: Initial efficacy and safety evaluation in cynomolgus monkeys. Treat-NMD/NIH Conference, Brussels, Belgium.
64. Sazani, P., Weller, D.L., and Shrewsbury, S.B. (2010). Safety pharmacology and genotoxicity evaluation of AVI-4658. Int. J. Toxicol. 29, 143-156.
65. Sazani, P., Ness, K.P., Weller, D.L., et al. (2011). Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of Duchenne muscular dystrophy. Int. J. Toxicol. 30, 313-321.
66. Stein, C.A., Subasinghe, C., Shinozuka, K., and Cohen, J.S. (1988). Physicochemical properties of phosphorothioate oligo-deoxynucleotides. Nucleic Acids Res. 16, 3209-3221.
67. Summerton, J., and Weller, D. (1997). Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7, 187-195.
68. Summerton, J., Stein, D., Huang, S.B., et al. (1997). Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev. 7, 63-70.
69. Takeshima, Y., Wada, H., Yagi, M., et al. (2001). Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Brain Dev. 23, 788-790.
70. Takeshima, Y., Yagi, M., Wada, H., and Matsuo, M. (2005). Intra-peritoneal administration of phosphorothioate antisense oligo-deoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle. Brain Dev. 27, 488-493.
71. Takeshima, Y., Yagi, M., Wada, H., et al. (2006). Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr. Res. 59, 690-694.
72. Tinsley, J.M., Blake, D.J., Zuellig, R.A., and Davies, K.E. (1994). Increasing complexity of the dystrophin-associated protein complex. Proc. Natl. Acad. Sci. U.S.A. 91, 8307-8313.
73. Townsend, D., Yasuda, S., Li, S., et al. (2008). Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol.Ther. 16, 832-835.
74. van Deutekom, J.C., Bremmer-Bout, M., Janson, A.A., et al. (2001). Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum. Mol. Genet. 10, 1547-1554.
75. van Deutekom, J.C., Janson, A.A., Ginjaar, I.B., et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 357, 2677-2686.
76. van Vliet, L., De Winter, C.L., van Deutekom, J.C., et al. (2008). Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy. BMC Med. Genet. 9, 105.
77. Wicksell, R.K., Kihlgren, M., Melin, L., and Eeg-Olofsson, O. (2004). Specific cognitive deficits are common in children with Duchenne muscular dystrophy. Dev. Med. Child Neurol. 46, 154-159.
78. Wu, B., Xiao, B., Cloer, C., et al. (2011). One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice. Mol. Ther. 19, 576-583.
79. Wu, B., Lu, P., Cloer, C., et al. (2012). Long-term rescue of dys-trophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. Am. J. Pathol. 181, 392-400.
80. Yin, H., Moulton, H.M., Seow, Y., et al. (2008). Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum. Mol. Genet. 17, 3909-3918.
81. Yin, H., Betts, C., Saleh, A.F., et al. (2010). Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol. Ther. 18, 819-827.
82. Yin, H., Saleh, A.F., Betts, C., et al. (2011). Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dys-trophin exon skipping in heart and phenotypic correction in mdx mice. Mol. Ther. 19, 1295-1303.
83. Yokota, T., Lu, Q.L., Partridge, T., et al. (2009). Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann. Neurol. 65, 667-676.
84. Yokota, T., Hoffman, E., and Takeda, S. (2011). Antisense oligo-mediated multiple exon skipping in a dog model of Duchenne muscular dystrophy. Methods Mol. Biol. 709, 299-312.